COMMUNIQUÉS West-GlobeNewswire

Microbix Unveils Test Controls for Head and Neck Cancer
11/03/2024
HPV-related Tissue-Sample Mimics for QC of histology and PCR analyses MISSISSAUGA, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, [...]
Transactions in connection with share buy-back program
11/03/2024
Company Announcement COPENHAGEN, Denmark; March 11, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock [...]
Major shareholder announcement – BlackRock, Inc.
11/03/2024
ANNOUNCEMENT NO. 253 Major shareholder announcement Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec [...]
Recursion Announces Plans to Open New Office in London
11/03/2024
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the heart of King’s [...]
SAFE - Bond financing agreement in a minimum amount of €850,000 to support the Group’s turnaround strategy
11/03/2024
Bond financing agreement in a minimum amount of €850,000 to support the Group’s turnaround strategy Eragny-sur-Oise – France – March 11, 2024, 8.00 a.m. Safe SA (the “Company” ) announces that it has arranged flexible [...]
SAFE - Accord de financement obligataire d’un montant minimum de 850 000 € pour accompagner la stratégie de retournement du Groupe
11/03/2024
Accord de financement obligataire d’un montant minimum de 850 000 € pour accompagner la stratégie de retournement du Groupe Eragny-sur-Oise - France - le 11 mars 2024 à 8h . Safe SA (la « Société ») annonce la mise en [...]
Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia
11/03/2024
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of [...]
ONWARD® Medical Accepted to New US FDA TAP Program for Development of its ARC-BCI™ System
11/03/2024
The Company is one of the first brain-computer interface entrants accepted into this program, intended to optimize the commercialization pathway for breakthrough medical technology EINDHOVEN, the Netherlands, March 11, [...]
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
11/03/2024
Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland
11/03/2024
Gdańsk, Poland – 11 March 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has received CGMP [...]
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
11/03/2024
Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial [...]
PHAXIAM Therapeutics annonce la réalisation du retrait volontaire de ses « American Depository Shares » du Nasdaq Stock Market
11/03/2024
Lyon (France) et Cambridge (MA, US), le 11 mars 2024, à 7h00 CET - PHAXIAM Therapeutics (Nasdaq & Euronext : PHXM), société biopharmaceutique qui développe des traitements innovants contre les infections [...]
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
11/03/2024
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD show sustained off-drug improvements of AD signs and symptoms with [...]
Communiqué de presse : De nouveaux résultats de phase II relatifs à l’amlitelimab confortent son potentiel de meilleur médicament de sa catégorie en termes de maintien de la réponse dans le traitement de la dermatite atopique
11/03/2024
De nouveaux résultats de phase II relatifs à l’amlitelimab confortent son potentiel de meilleur médicament de sa catégorie en termes de maintien de la réponse dans le traitement de la dermatite atopique Des données de [...]
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
11/03/2024
NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA supports an accelerated [...]
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
10/03/2024
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 1 39.4% of children treated with [...]
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
10/03/2024
MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the ARGO trial of [...]
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
09/03/2024
Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signature Suggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific pattern [...]
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
09/03/2024
– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested; sustained maximal target inhibition safely achieved at top dose – – Open label extension (OLE) study [...]

Pages